Plain-English translation of NCT03621904 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
This study is testing whether doctors can predict which women with advanced or recurrent endometrial cancer will respond well to hormone therapy by studying their tumor tissue. Researchers will look at tumor samples from patients receiving hormone therapy and compare how well the treatment works based on the tumor's characteristics. The goal is to help future patients and their doctors make smarter decisions about which treatments are worth trying.
Right now, doctors decide whether to use hormone therapy largely based on their own experience rather than scientific evidence. This medication has fewer side effects than chemotherapy and is better tolerated by older women with other health conditions—but we don't know how to predict who will benefit most. This study aims to fill that gap by finding biological markers that can tell us upfront who is likely to respond.
You likely qualify if…
You likely don't qualify if…
If you join this study, researchers will obtain and analyze your tumor biopsy sample to look for specific markers that predict how well hormone therapy will work for you. You'll receive your planned hormone therapy as usual—the study doesn't change your treatment. The main contribution is allowing doctors to study your tumor tissue to build knowledge that will help future patients.
AI-generated summary from trial data · Jun 4, 2026 · Not medical advice
Netherlands
Sponsor
Radboud University Medical Center
Collaborators
Haukeland University Hospital, Maastricht University Medical Center
Enrollment target
~150 participants
Started
October 2022
Primary completion
October 2026
Age range
18 Years – 110 Years
Sex
Female only
Last updated on clinicaltrials.gov in January 2023.
Reach out to the team running this trial. Response times vary — some teams are faster than others.
Central contact
Maartje Luijten, MD
Radboud University Medical Center
Tell us you're interested and we'll help connect you with the research team. We'll walk you through what to expect first — no email needed to get started.